Growth Disorders
Silver-Russell Syndrome
Dwarfism
Beckwith-Wiedemann Syndrome
Hair Follicle
Genomic Imprinting
Body Height
Insulin-Like Growth Factor II
Bipolar Disorder
Mental Disorders
Diagnostic and Statistical Manual of Mental Disorders
Depressive Disorder, Major
Attention Deficit Disorder with Hyperactivity
Depressive Disorder
Obsessive-Compulsive Disorder
Stress Disorders, Post-Traumatic
Autistic Disorder
Phobic Disorders
Child Development Disorders, Pervasive
Psychotic Disorders
Pathological changes in chickens, ducks and turkeys fed high levels of rapeseed oil. (1/1579)
Rations containing 25% of either regular rapeseed oil (36% erucic acid), Oro rapeseed oil (1.9% erucic acid), soybean oil or a mixture of lard and corn oil were fed to chickens, ducks and turkeys. The regular rapeseed oil ration caused growth depression, increased feed conversion and anemia in all species. All the ducks and some of the chickens fed the regular rapeseed oil ration died. These dead birds were affected with hydropericardium and ascites. No deaths in the turkeys could be attributed to the regular rapeseed oil ration but some turkeys fed this ration had degenerative foci characterized by infiltrations of histiocytic and giant cells in the myocardium. Severe fatty change in the heart, skeletal muscles, spleen and kidney was found at an early age in all birds fed the regular rapeseed oil ration. Less severe fatty change but no other lesions were found in birds fed the Oro rapeseed oil and soybean oil rations. (+info)Changes in body composition and leptin levels during growth hormone (GH) treatment in short children with various GH secretory capacities. (2/1579)
OBJECTIVE: The aim of this study was to follow changes in body composition, estimated by dual-energy X-ray absorptiometry (DXA), in relation to changes in leptin during the first year of GH therapy in order to test the hypothesis that leptin is a metabolic signal involved in the regulation of GH secretion in children. DESIGN AND METHODS: In total, 33 prepubertal children were investigated. Their mean (S.D.) chronological age at the start of GH treatment was 11.5 (1.6) years, and their mean height was -2.33 (0.38) S.D. scores (SDS). GH was administered subcutaneously at a daily dose of 0.1 (n=26) or 0.2 (n=7) IU/kg body weight. Ten children were in the Swedish National Registry for children with GH deficiency, and twenty-three children were involved in trials of GH treatment for idiopathic short stature. Spontaneous 24-h GH secretion was studied in 32 of the children. In the 24-h GH profiles, the maximum level of GH was determined and the secretion rate estimated by deconvolution analysis (GHt). Serum leptin levels were measured at the start of GH treatment and after 10 and 30 days and 3, 6 and 12 months of treatment. Body composition measurements, by DXA, were performed at baseline and 12 months after the onset of GH treatment. RESULTS: After 12 months of GH treatment, mean height increased from -2.33 to -1.73 SDS and total body fat decreased significantly by 3.0 (3.3)%. Serum leptin levels were decreased significantly at all time points studied compared with baseline. There was a significant correlation between the change in total body fat and the change in serum leptin levels during the 12 months of GH treatment, whereas the leptin concentration per unit fat mass did not change. In a multiple stepwise linear regression analysis with 12 month change in leptin levels as the dependent variable, the percentage change in fat over 12 months, the baseline fat mass (%) of body mass and GHt accounted for 24.0%, 11.5% and 12.2% of the variability respectively. CONCLUSIONS: There are significant correlations between changes in leptin and fat and endogenous GH secretion in short children with various GH secretory capacities. Leptin may be the messenger by which the adipose tissue affects hypothalamic regulation of GH secretion. (+info)Separate and joint effects of micronutrient deficiencies on linear growth. (3/1579)
Recent studies have investigated the effect of micronutrient deficiencies on growth stunting, with special attention toward the effect of zinc, iron, vitamin A and iodine deficiencies. In Mexico, the prevalence of growth stunting in children <5 y old is approximately 24%; it is higher in rural areas and lower in urban areas. In an initial study, the effect of zinc and/or iron supplementation on linear growth was investigated in a longitudinal, placebo-controlled design. After 12 mo of supplementation, there was no difference between the groups supplemented with zinc, iron or zinc plus iron and the placebo group. At baseline, 82% of the children in this study were deficient in at least two out of the five micronutrients that were determined, and 73% were anemic. In another study, a mixture of those micronutrients that were documented to be lacking in Mexican children was formulated in a supplement and given to Mexican children over a period of 12 mo in a longitudinal, placebo-controlled, supplementation design. Children in the low and medium socioeconomic status grew about 1 cm more than similar children in the placebo group. This difference was not found in children of high socioeconomic status. It is suggested that, in most cases, growth stunting is associated with marginal deficiencies of several micronutrients and that in populations with multiple micronutrient deficiencies, the effect on linear growth of supplementation with single nutrients will not be significant. Supplementation with multiple micronutrients is expected to be more effective, but even in that case the actual increment in height was less than the expected potential increment. (+info)Burden of infection on growth failure. (4/1579)
The high prevalence of infections among children living in poor areas of developing countries impairs linear growth in these populations. Acute, invasive infections, which provoke a systemic response (e.g., dysentery and pneumonia), and chronic infections, which affect the host over a sustained period (e.g., gut helminth infections), have a substantial effect on linear growth. Such infections can diminish linear growth by affecting nutritional status. This occurs because infections may decrease food intake, impair nutrient absorption, cause direct nutrient losses, increase metabolic requirements or catabolic losses of nutrients and, possibly, impair transport of nutrients to target tissues. In addition, induction of the acute phase response and production of proinflammatory cytokines may directly affect the process of bone remodeling that is required for long bone growth. Infection of cells directly involved in bone remodeling (osteoclasts or osteoblasts) by specific viruses may also directly affect linear growth. Many interventions are possible to diminish the effect of infection on growth. Prevention of disease through sanitation, vector control, promotion of breast-feeding and vaccination is crucial. Appropriate treatment of infections (e.g., antibiotics for pneumonia) as well as supportive nutritional therapy (again including breast-feeding) during and after recovery, is also important. Targeted therapeutic interventions to decrease the prevalence of gut helminth infections may also be appropriate in areas in which such infections are widespread. Such interventions are of public health benefit not only because they reduce the incidence or severity of infections, but also because they decrease the long-term detrimental effect of malnutrition on populations. (+info)Retarded growth and deficits in the enteric and parasympathetic nervous system in mice lacking GFR alpha2, a functional neurturin receptor. (5/1579)
Glial cell line-derived neurotrophic factor (GDNF) and a related protein, neurturin (NTN), require a GPI-linked coreceptor, either GFR alpha1 or GFR alpha2, for signaling via the transmembrane Ret tyrosine kinase. We show that mice lacking functional GFR alpha2 coreceptor (Gfra2-/-) are viable and fertile but have dry eyes and grow poorly after weaning, presumably due to malnutrition. While the sympathetic innervation appeared normal, the parasympathetic cholinergic innervation was almost absent in the lacrimal and salivary glands and severely reduced in the small bowel. Neurite outgrowth and trophic effects of NTN at low concentrations were lacking in Gfra2-/- trigeminal neurons in vitro, whereas responses to GDNF were similar between the genotypes. Thus, GFR alpha2 is a physiological NTN receptor, essential for the development of specific postganglionic parasympathetic neurons. (+info)Cloning and expression of a novel chicken sulfotransferase cDNA regulated by GH. (6/1579)
We have used mRNA differential display to compare gene expression in normal and GH receptor-deficient dwarf chickens, and report here the characterization of one differentially expressed gene, which shows significant sequence identity to the sulfotransferase gene family. Partial cDNA clones were isolated from a chicken liver cDNA library and an additional sequence was obtained using 5' rapid amplification of cDNA ends. A complete cDNA probe hybridizes to three transcripts (2.4, 2.0 and 1.45 kb) on Northern blots of chicken liver RNA, which differ in the length of the 3' untranslated region. All three transcripts are expressed at higher levels in normal vs dwarf chickens, as expected for a GH-regulated gene. The expression of this sulfotransferase mRNA was also detected in skeletal muscle, but not other tissues. The administration of GH to chickens increased the hepatic expression within 1 h, suggesting this sulfotransferase could be directly regulated by GH. Sulfotransferase activity, using estradiol or corticosterone as substrate, is detected in cells transfected with an expression vector containing the full-length cDNA. The sequence of this sulfotransferase does not show significant similarity with any subfamily of the sulfotransferases and its endogenous substrate is presently unknown. However, we speculate that GH activation of sulfotransferase activity could play a role in reducing concentrations of growth-antagonistic steroid hormones in GH target tissues. These results demonstrate the usefulness of differential display in this model system to identify genes that play a role in mediating GH action. (+info)Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development. (7/1579)
BACKGROUND: Learning disability and short stature are cardinal signs of Down's syndrome. Insulin-like growth factor I (IGF-I), regulated by growth hormone (GH) from about 6 months of age, may be involved in brain development. AIMS: To study long term effects of GH on linear growth and psychomotor development in young children with Down's syndrome. Study design-Fifteen children with Down's syndrome were treated with GH for three years from the age of 6 to 9 months (mean, 7.4). Linear growth, psychomotor development, skeletal maturation, serum concentrations of IGF-I and its binding proteins (BPs), and cerebrospinal fluid (CSF) concentrations of IGF-II were studied. RESULTS: The mean height of the study group increased from -1.8 to -0.8 SDS (Swedish standard) during treatment, whereas that of a Down's syndrome control group fell from -1.7 to -2.2 SDS. Growth velocity declined after treatment stopped. Head growth did not accelerate during treatment. No significant difference in mental or gross motor development was found. The low concentrations of serum IGF-I and IGFBP-3 became normal during GH treatment. CONCLUSIONS: GH treatment results in normal growth velocity in Down's syndrome but does not affect head circumference or mental or gross motor development. Growth velocity declines after treatment stops. (+info)Generalised uridine diphosphate galactose-4-epimerase deficiency. (8/1579)
The generalised form of epimerase deficiency galactosaemia has been described in only two children from unrelated families. Their progress is reported and three other affected children from these families are described. The initial presentation was similar to classic galactosaemia. Despite treatment all have shown poor growth and moderate learning difficulties. Three have sensorineural deafness and four have pronounced dysmorphic features. The two older female patients have normal pubertal development. (+info)Growth disorders are medical conditions that affect a person's growth and development, leading to shorter or taller stature than expected for their age, sex, and ethnic group. These disorders can be caused by various factors, including genetic abnormalities, hormonal imbalances, chronic illnesses, malnutrition, and psychosocial issues.
There are two main types of growth disorders:
1. Short stature: This refers to a height that is significantly below average for a person's age, sex, and ethnic group. Short stature can be caused by various factors, including genetic conditions such as Turner syndrome or dwarfism, hormonal deficiencies, chronic illnesses, malnutrition, and psychosocial issues.
2. Tall stature: This refers to a height that is significantly above average for a person's age, sex, and ethnic group. Tall stature can be caused by various factors, including genetic conditions such as Marfan syndrome or Klinefelter syndrome, hormonal imbalances, and certain medical conditions like acromegaly.
Growth disorders can have significant impacts on a person's physical, emotional, and social well-being. Therefore, it is essential to diagnose and manage these conditions early to optimize growth and development and improve overall quality of life. Treatment options for growth disorders may include medication, nutrition therapy, surgery, or a combination of these approaches.
Silver-Russell Syndrome (SRS) is a rare genetic disorder characterized by intrauterine and postnatal growth retardation, relative macrocephaly at birth with subsequent normalization of head circumference, a prominent forehead (frontal bossing), a small jaw (micrognathia), body asymmetry, and feeding difficulties in early life. Some individuals may also have clinodactyly (curving of the fifth finger towards the fourth), wide-spaced fifth fingers, and downturned corners of the mouth.
The genetic basis for SRS is heterogeneous, but the most common genetic abnormality associated with this syndrome is hypomethylation of the H19/IGF2:IG-DMR (imprinting control region) on chromosome 11p15.5. This region regulates the expression of two neighboring genes, IGF2 and H19, which are imprinted and expressed in a parent-of-origin-specific manner. In SRS, the hypomethylation leads to decreased IGF2 expression and increased H19 expression, which is thought to contribute to the growth retardation observed in this syndrome.
Individuals with SRS may have developmental delays, learning disabilities, and behavioral problems, although their cognitive abilities can range from normal to mildly impaired. They are also at an increased risk of developing certain medical conditions, such as low blood sugar (hypoglycemia), heart defects, kidney abnormalities, and a higher risk of childhood cancer, particularly Wilms' tumor.
Diagnosis of SRS is typically based on clinical criteria, including growth parameters, physical features, and developmental history. Genetic testing for hypomethylation at the H19/IGF2:IG-DMR region can confirm the diagnosis in many cases. Management of SRS involves a multidisciplinary approach, with interventions focused on addressing specific symptoms and promoting optimal growth and development.
Dwarfism is a medical condition that is characterized by short stature, typically with an adult height of 4 feet 10 inches (147 centimeters) or less. It is caused by a variety of genetic and medical conditions that affect bone growth, including skeletal dysplasias, hormonal deficiencies, and chromosomal abnormalities.
Skeletal dysplasias are the most common cause of dwarfism and are characterized by abnormalities in the development and growth of bones and cartilage. Achondroplasia is the most common form of skeletal dysplasia, accounting for about 70% of all cases of dwarfism. It is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene and results in short limbs, a large head, and a prominent forehead.
Hormonal deficiencies, such as growth hormone deficiency or hypothyroidism, can also cause dwarfism if they are not diagnosed and treated early. Chromosomal abnormalities, such as Turner syndrome (monosomy X) or Down syndrome (trisomy 21), can also result in short stature and other features of dwarfism.
It is important to note that people with dwarfism are not "dwarves" - the term "dwarf" is a medical and sociological term used to describe individuals with this condition, while "dwarves" is a term often used in fantasy literature and media to refer to mythical beings. The use of the term "dwarf" can be considered disrespectful or offensive to some people with dwarfism, so it is important to use respectful language when referring to individuals with this condition.
Beckwith-Wiedemann syndrome (BWS) is a genetic overgrowth disorder that affects several parts of the body. It is characterized by an increased risk of developing certain tumors, especially during the first few years of life. The symptoms and features of BWS can vary widely among affected individuals.
The medical definition of Beckwith-Wiedemann syndrome includes the following major criteria:
1. Excessive growth before birth (macrosomia) or in infancy (infantile gigantism)
2. Enlargement of the tongue (macroglossia)
3. Abdominal wall defects, such as an omphalocele (protrusion of abdominal organs through the belly button) or a diastasis recti (separation of the abdominal muscles)
4. Enlargement of specific internal organs, like the kidneys, liver, or pancreas
5. A distinctive facial appearance, which may include ear creases or pits, wide-set eyes, and a prominent jaw
Additional findings in BWS can include:
1. Increased risk of developing embryonal tumors, such as Wilms tumor (a type of kidney cancer), hepatoblastoma (a liver cancer), and neuroblastoma (a nerve tissue cancer)
2. Hypoglycemia (low blood sugar) in infancy due to hyperinsulinism (overproduction of insulin)
3. Asymmetric growth, where one side of the body or a specific region is significantly larger than the other
4. Ear abnormalities, such as cupped ears or low-set ears
5. Developmental delays and learning disabilities in some cases
Beckwith-Wiedemann syndrome is caused by changes in the chromosome 11p15 region, which contains several genes that regulate growth and development. The most common cause of BWS is an epigenetic abnormality called paternal uniparental disomy (UPD), where both copies of this region come from the father instead of one copy from each parent. Other genetic mechanisms, such as mutations in specific genes or imprinting center defects, can also lead to BWS.
The diagnosis of Beckwith-Wiedemann syndrome is typically based on clinical findings and confirmed by molecular testing. Management includes regular monitoring for tumor development, controlling hypoglycemia, and addressing any other complications as needed. Surgical intervention may be required in cases of organ enlargement or structural abnormalities. Genetic counseling is recommended for affected individuals and their families to discuss the risks of recurrence and available reproductive options.
A hair follicle is a part of the human skin from which hair grows. It is a complex organ that consists of several layers, including an outer root sheath, inner root sheath, and matrix. The hair follicle is located in the dermis, the second layer of the skin, and is surrounded by sebaceous glands and erector pili muscles.
The hair growth cycle includes three phases: anagen (growth phase), catagen (transitional phase), and telogen (resting phase). During the anagen phase, cells in the matrix divide rapidly to produce new hair fibers that grow out of the follicle. The hair fiber is made up of a protein called keratin, which also makes up the outer layers of the skin and nails.
Hair follicles are important for various biological functions, including thermoregulation, sensory perception, and social communication. They also play a role in wound healing and can serve as a source of stem cells that can differentiate into other cell types.
Genomic imprinting is a epigenetic process that leads to the differential expression of genes depending on their parental origin. It involves the methylation of certain CpG sites in the DNA, which results in the silencing of one of the two copies of a gene, either the maternal or paternal allele. This means that only one copy of the gene is active and expressed, while the other is silent.
This phenomenon is critical for normal development and growth, and it plays a role in the regulation of genes involved in growth and behavior. Genomic imprinting is also associated with certain genetic disorders, such as Prader-Willi and Angelman syndromes, which occur when there are errors in the imprinting process that lead to the absence or abnormal expression of certain genes.
It's important to note that genomic imprinting is a complex and highly regulated process that is not yet fully understood. Research in this area continues to provide new insights into the mechanisms underlying gene regulation and their impact on human health and disease.
"Body height" is a measure of the vertical length of a person's body from the top of their head to the bottom of their feet. It is typically measured in units such as centimeters (cm) or inches (in). In medical settings, body height is often used as a basic anthropometric measurement to assess overall health status, growth and development, nutritional status, and aging-related changes.
There are different methods for measuring body height, but the most common one involves having the person stand upright against a vertical surface (such as a wall or a stadiometer) with their heels, buttocks, shoulders, and head touching the surface. The measurement is taken at the point where the top of the person's head meets the surface.
Body height can be influenced by various factors, including genetics, nutrition, health status, and environmental conditions. Changes in body height over time can provide important insights into a person's health trajectory and potential health risks. For example, a significant decrease in body height may indicate bone loss or spinal compression, while a rapid increase in height during childhood or adolescence may suggest optimal growth and development.
Insulin-like Growth Factor II (IGF-II) is a growth factor that is structurally and functionally similar to insulin. It is a single-chain polypeptide hormone, primarily produced by the liver under the regulation of growth hormone. IGF-II plays an essential role in fetal growth and development, and continues to have important functions in postnatal life, including promoting cell growth, proliferation, and differentiation in various tissues.
IGF-II binds to and activates the IGF-I receptor and the insulin receptor, leading to intracellular signaling cascades that regulate metabolic and mitogenic responses. Dysregulation of IGF-II expression and signaling has been implicated in several pathological conditions, such as cancer, growth disorders, and diabetes.
It is important to note that IGF-II should not be confused with Insulin-like Growth Factor I (IGF-I), which is another hormone with structural and functional similarities to insulin but has distinct roles in growth and development.
Bipolar disorder, also known as manic-depressive illness, is a mental health condition that causes extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). When you become depressed, you may feel sad or hopeless and lose interest or pleasure in most activities. When your mood shifts to mania or hypomania (a less severe form of mania), you may feel euphoric, full of energy, or unusually irritable. These mood swings can significantly affect your job, school, relationships, and overall quality of life.
Bipolar disorder is typically characterized by the presence of one or more manic or hypomanic episodes, often accompanied by depressive episodes. The episodes may be separated by periods of normal mood, but in some cases, a person may experience rapid cycling between mania and depression.
There are several types of bipolar disorder, including:
* Bipolar I Disorder: This type is characterized by the occurrence of at least one manic episode, which may be preceded or followed by hypomanic or major depressive episodes.
* Bipolar II Disorder: This type involves the presence of at least one major depressive episode and at least one hypomanic episode, but no manic episodes.
* Cyclothymic Disorder: This type is characterized by numerous periods of hypomania and depression that are not severe enough to meet the criteria for a full manic or depressive episode.
* Other Specified and Unspecified Bipolar and Related Disorders: These categories include bipolar disorders that do not fit the criteria for any of the other types.
The exact cause of bipolar disorder is unknown, but it appears to be related to a combination of genetic, environmental, and neurochemical factors. Treatment typically involves a combination of medication, psychotherapy, and lifestyle changes to help manage symptoms and prevent relapses.
A mental disorder is a syndrome characterized by clinically significant disturbance in an individual's cognition, emotion regulation, or behavior. It's associated with distress and/or impaired functioning in social, occupational, or other important areas of life, often leading to a decrease in quality of life. These disorders are typically persistent and can be severe and disabling. They may be related to factors such as genetics, early childhood experiences, or trauma. Examples include depression, anxiety disorders, bipolar disorder, schizophrenia, and personality disorders. It's important to note that a diagnosis should be made by a qualified mental health professional.
Anxiety disorders are a category of mental health disorders characterized by feelings of excessive and persistent worry, fear, or anxiety that interfere with daily activities. They include several different types of disorders, such as:
1. Generalized Anxiety Disorder (GAD): This is characterized by chronic and exaggerated worry and tension, even when there is little or nothing to provoke it.
2. Panic Disorder: This is characterized by recurring unexpected panic attacks and fear of experiencing more panic attacks.
3. Social Anxiety Disorder (SAD): Also known as social phobia, this is characterized by excessive fear, anxiety, or avoidance of social situations due to feelings of embarrassment, self-consciousness, and concern about being judged or viewed negatively by others.
4. Phobias: These are intense, irrational fears of certain objects, places, or situations. When a person with a phobia encounters the object or situation they fear, they may experience panic attacks or other severe anxiety responses.
5. Agoraphobia: This is a fear of being in places where it may be difficult to escape or get help if one has a panic attack or other embarrassing or incapacitating symptoms.
6. Separation Anxiety Disorder (SAD): This is characterized by excessive anxiety about separation from home or from people to whom the individual has a strong emotional attachment (such as a parent, sibling, or partner).
7. Selective Mutism: This is a disorder where a child becomes mute in certain situations, such as at school, but can speak normally at home or with close family members.
These disorders are treatable with a combination of medication and psychotherapy (cognitive-behavioral therapy, exposure therapy). It's important to seek professional help if you suspect that you or someone you know may have an anxiety disorder.
Mood disorders are a category of mental health disorders characterized by significant and persistent changes in mood, affect, and emotional state. These disorders can cause disturbances in normal functioning and significantly impair an individual's ability to carry out their daily activities. The two primary types of mood disorders are depressive disorders (such as major depressive disorder or persistent depressive disorder) and bipolar disorders (which include bipolar I disorder, bipolar II disorder, and cyclothymic disorder).
Depressive disorders involve prolonged periods of low mood, sadness, hopelessness, and a lack of interest in activities. Individuals with these disorders may also experience changes in sleep patterns, appetite, energy levels, concentration, and self-esteem. In severe cases, they might have thoughts of death or suicide.
Bipolar disorders involve alternating episodes of mania (or hypomania) and depression. During a manic episode, individuals may feel extremely elated, energetic, or irritable, with racing thoughts, rapid speech, and impulsive behavior. They might engage in risky activities, have decreased sleep needs, and display poor judgment. In contrast, depressive episodes involve the same symptoms as depressive disorders.
Mood disorders can be caused by a combination of genetic, biological, environmental, and psychological factors. Proper diagnosis and treatment, which may include psychotherapy, medication, or a combination of both, are essential for managing these conditions and improving quality of life.
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a publication of the American Psychiatric Association (APA) that provides diagnostic criteria for mental disorders. It is widely used by mental health professionals in the United States and around the world to diagnose and classify mental health conditions.
The DSM includes detailed descriptions of symptoms, clinical examples, and specific criteria for each disorder, which are intended to facilitate accurate diagnosis and improve communication among mental health professionals. The manual is regularly updated to reflect current research and clinical practice, with the most recent edition being the DSM-5, published in 2013.
It's important to note that while the DSM is a valuable tool for mental health professionals, it is not without controversy. Some critics argue that the manual medicalizes normal human experiences and that its categories may be too broad or overlapping. Nonetheless, it remains an essential resource for clinicians, researchers, and policymakers in the field of mental health.
Major Depressive Disorder (MDD), also simply referred to as depression, is a serious mental health condition characterized by the presence of one or more major depressive episodes. A major depressive episode is a period of at least two weeks during which an individual experiences a severely depressed mood and/or loss of interest or pleasure in nearly all activities, accompanied by at least four additional symptoms such as significant changes in appetite or weight, sleep disturbances, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive guilt, difficulty thinking, concentrating, or making decisions, and recurrent thoughts of death or suicide.
MDD can significantly impair an individual's ability to function in daily life, and it is associated with increased risks of suicide, substance abuse, and other mental health disorders. The exact cause of MDD is not fully understood, but it is believed to result from a complex interplay of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of psychotherapy (such as cognitive-behavioral therapy) and medication (such as selective serotonin reuptake inhibitors or tricyclic antidepressants).
Attention Deficit Hyperactivity Disorder (ADHD) with hyperactivity is a neurodevelopmental disorder that affects both children and adults. The condition is characterized by symptoms including:
1. Difficulty paying attention or staying focused on a single task
2. Impulsivity, or acting without thinking
3. Hyperactivity, or excessive fidgeting, restlessness, or talking
In order to be diagnosed with ADHD with hyperactivity, an individual must exhibit these symptoms to a degree that is developmentally inappropriate and interferes with their daily functioning. Additionally, the symptoms must have been present for at least six months and be present in multiple settings (e.g., at home, school, work).
It's important to note that ADHD can manifest differently in different people, and some individuals may experience predominantly inattentive or impulsive symptoms rather than hyperactive ones. However, when the hyperactive component is prominent, it is referred to as ADHD with hyperactivity.
Effective treatments for ADHD with hyperactivity include a combination of medication (such as stimulants) and behavioral therapy. With appropriate treatment, individuals with ADHD can learn to manage their symptoms and lead successful, fulfilling lives.
A depressive disorder is a mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest or pleasure in activities. It can also include changes in sleep, appetite, energy levels, concentration, and self-esteem, as well as thoughts of death or suicide. Depressive disorders can vary in severity and duration, with some people experiencing mild and occasional symptoms, while others may have severe and chronic symptoms that interfere with their ability to function in daily life.
There are several types of depressive disorders, including major depressive disorder (MDD), persistent depressive disorder (PDD), and postpartum depression. MDD is characterized by symptoms that interfere significantly with a person's ability to function and last for at least two weeks, while PDD involves chronic low-grade depression that lasts for two years or more. Postpartum depression occurs in women after childbirth and can range from mild to severe.
Depressive disorders are thought to be caused by a combination of genetic, biological, environmental, and psychological factors. Treatment typically involves a combination of medication, psychotherapy (talk therapy), and lifestyle changes.
Obsessive-Compulsive Disorder (OCD) is a mental health disorder characterized by the presence of obsessions and compulsions. Obsessions are recurrent and persistent thoughts, urges, or images that are intrusive, unwanted, and often distressing. Compulsions are repetitive behaviors or mental acts that an individual feels driven to perform in response to an obsession or according to rigid rules, and which are aimed at preventing or reducing anxiety or distress, or preventing some dreaded event or situation. These obsessions and/or compulsions cause significant distress, take up a lot of time (an hour or more a day), and interfere with the individual's daily life, including social activities, relationships, and work or school performance. OCD is considered a type of anxiety disorder and can also co-occur with other mental health conditions.
Post-traumatic stress disorder (PTSD) is a psychiatric condition that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, serious accident, war combat, rape, or violent personal assault. According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), PTSD is characterized by the following symptoms, which must last for more than one month:
1. Intrusion symptoms: These include distressing memories, nightmares, flashbacks, or intense psychological distress or reactivity to internal or external cues that symbolize or resemble an aspect of the traumatic event.
2. Avoidance symptoms: Persistent avoidance of stimuli associated with the traumatic event, including thoughts, feelings, conversations, activities, places, or people.
3. Negative alterations in cognitions and mood: This includes negative beliefs about oneself, others, or the world; distorted blame of self or others for causing the trauma; persistent negative emotional state; decreased interest in significant activities; and feelings of detachment or estrangement from others.
4. Alterations in arousal and reactivity: This includes irritable behavior and angry outbursts, reckless or self-destructive behavior, hypervigilance, exaggerated startle response, problems with concentration, and sleep disturbance.
5. Duration of symptoms: The symptoms must last for more than one month.
6. Functional significance: The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
It is essential to note that PTSD can occur at any age and can be accompanied by various physical and mental health problems, such as depression, substance abuse, memory problems, and other difficulties in cognition. Appropriate treatment, which may include psychotherapy, medication, or a combination of both, can significantly improve the symptoms and overall quality of life for individuals with PTSD.
Autistic Disorder, also known as Autism or Classic Autism, is a neurodevelopmental disorder that affects communication and behavior. It is characterized by:
1. Persistent deficits in social communication and social interaction across multiple contexts, including:
* Deficits in social-emotional reciprocity;
* Deficits in nonverbal communicative behaviors used for social interaction;
* Deficits in developing, maintaining, and understanding relationships.
2. Restricted, repetitive patterns of behavior, interests, or activities, as manifested by at least two of the following:
* Stereotyped or repetitive motor movements, use of objects, or speech;
* Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal or nonverbal behavior;
* Highly restricted, fixated interests that are abnormal in intensity or focus;
* Hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment.
3. Symptoms must be present in the early developmental period (but may not become fully manifest until social demands exceed limited capacities) and limit or impair everyday functioning.
4. Symptoms do not occur exclusively during the course of a schizophrenia spectrum disorder or other psychotic disorders.
Autistic Disorder is part of the autism spectrum disorders (ASDs), which also include Asperger's Syndrome and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). The current diagnostic term for this category of conditions, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is Autism Spectrum Disorder.
A phobic disorder is a type of anxiety disorder characterized by an excessive and irrational fear or avoidance of specific objects, situations, or activities. This fear can cause significant distress and interfere with a person's daily life. Phobic disorders are typically classified into three main categories: specific phobias (such as fear of heights, spiders, or needles), social phobia (or social anxiety disorder), and agoraphobia (fear of open spaces or situations where escape might be difficult).
People with phobic disorders often recognize that their fear is excessive or unreasonable, but they are unable to control it. When exposed to the feared object or situation, they may experience symptoms such as rapid heartbeat, sweating, trembling, and difficulty breathing. These symptoms can be so distressing that individuals with phobic disorders go to great lengths to avoid the feared situation, which can have a significant impact on their quality of life.
Treatment for phobic disorders typically involves cognitive-behavioral therapy (CBT), which helps individuals identify and challenge their irrational thoughts and fears, as well as exposure therapy, which gradually exposes them to the feared object or situation in a safe and controlled environment. In some cases, medication may also be recommended to help manage symptoms of anxiety.
Pervasive developmental disorders (PDD) are a group of conditions that affect the development and functioning of the brain, leading to delays in many areas of development. The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) has replaced the term "pervasive developmental disorders" with "autism spectrum disorder" and "other neurodevelopmental disorders."
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction across multiple contexts, as well as restricted, repetitive patterns of behavior, interests, or activities. The symptoms of ASD can range from mild to severe, and the condition affects approximately 1 in 54 children in the United States.
Other neurodevelopmental disorders that were previously classified as PDDs include:
1. Intellectual disability (ID): a condition characterized by significant limitations in intellectual functioning and adaptive behavior, which covers many everyday social and practical skills. This disorder used to be referred to as "mental retardation."
2. Communication disorders: these are disorders that affect an individual's ability to communicate, including language disorders, speech sound disorders, and stuttering.
3. Attention-deficit/hyperactivity disorder (ADHD): a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity.
4. Specific learning disorder: a neurodevelopmental disorder that affects an individual's ability to learn and use specific academic skills, such as reading, writing, or mathematics.
5. Motor disorders: these are disorders that affect an individual's movement and coordination, including developmental coordination disorder, stereotypic movement disorder, and tic disorders.
The medical definition of 'Child Development Disorders, Pervasive' has been replaced with more specific diagnoses in the DSM-5 to better reflect the diverse nature of these conditions and improve diagnostic accuracy and treatment planning.
Psychotic disorders are a group of severe mental health conditions characterized by distorted perceptions, thoughts, and emotions that lead to an inability to recognize reality. The two most common symptoms of psychotic disorders are hallucinations and delusions. Hallucinations are when a person sees, hears, or feels things that aren't there, while delusions are fixed, false beliefs that are not based on reality.
Other symptoms may include disorganized speech, disorganized behavior, catatonic behavior, and negative symptoms such as apathy and lack of emotional expression. Schizophrenia is the most well-known psychotic disorder, but other types include schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, and substance-induced psychotic disorder.
Psychotic disorders can be caused by a variety of factors, including genetics, brain chemistry imbalances, trauma, and substance abuse. Treatment typically involves a combination of medication, therapy, and support services to help manage symptoms and improve quality of life.
Substance-related disorders, as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), refer to a group of conditions caused by the use of substances such as alcohol, drugs, or medicines. These disorders are characterized by a problematic pattern of using a substance that leads to clinically significant impairment or distress. They can be divided into two main categories: substance use disorders and substance-induced disorders. Substance use disorders involve a pattern of compulsive use despite negative consequences, while substance-induced disorders include conditions such as intoxication, withdrawal, and substance/medication-induced mental disorders. The specific diagnosis depends on the type of substance involved, the patterns of use, and the presence or absence of physiological dependence.
Hybrid growth disorders
Research for Growth Disorders Video | Children's National
Imaging of Skeletal Disorders Caused by Fibroblast Growth Factor Receptor Gene Mutations
Clinical and Humanistic Aspects of Growth Hormone Deficiency and Growth-Related Disorders
Kidshealth: A to Z: Growth Disorder | Akron Children's Hospital
Autologous Cell Therapy Market: Rise in Prevalence of Autoimmune Disorders, Cancer, Neurodegenerative Disease Boost Market...
East Forum 2015 "Global Dis(Order): Can International Trade Agreements revive growth?" | ECFR
Health Issues in Adulthood: Imprinting growth restriction disorders - Child Growth Foundation
Overview of Hair Growth - Skin Disorders - MSD Manual Consumer Version
Musculoskeletal Disorders Drugs Market Size 2022 And Growth Analysis
Spinal Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033
Despite launch of seven pipeline agents, bipolar disorder market will see only modest growth due to persistent generic erosion,...
Transforming growth factor-β stimulates nerve growth factor production in osteoarthritic synovium | BMC Musculoskeletal...
Childhood Interstitial Lung Disease (ChILD): Practice Essentials, Pathophysiology, Etiology
Growth disorders
Videos • growth disorders
Short stature: MedlinePlus Medical Encyclopedia
Growth retardation - Eating Disorders Glossary
Growth Problems (for Teens) - Children's Health System - Alabama (iFrame)
Bipolar Disorder - Market, Report Size, Worth, Revenue, Growth, Industry Value, Share 2023
Chronic Renal Insufficiency| Growth Disorders | PfizerPro UK
Types of growth disorders | More Than Height
